Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - BEVACIZUMAB INJECTION APPROVED FOR MARKETING2023.03.03
-
VOLUNTARY ANNOUNCEMENT - THREE PRODUCTS APPROVED FOR MARKETING2023.03.01
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 20232023.03.01
-
NEXT DAY DISCLOSURE RETURN2023.02.28
-
NEXT DAY DISCLOSURE RETURN2023.02.24
-
NEXT DAY DISCLOSURE RETURN2023.02.20
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF “LIMAPROST TABLETS” FOR MARKETING2023.02.20
-
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF INNOVATIVE MEDICINE "TQB2103 (Claudin18.2 ADC)" ACCEPTED BY CDE2023.02.10